EyeGate Pharmaceuticals was a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The company's lead product candidate was EGP-437, which utilized a proprietary iontophoretic drug delivery system. EyeGate underwent a name change to Kiora Pharmaceuticals in November 2021.